A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics

Abstract excerpt

Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of developing treatment-emergent anti-drug antibodies (TE-ADA) and presence of pre-existing ADA in drug-naïve individuals as risk-profiling strategies. Pre-existing ADAs...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biosimilars and Bioanalytical Methods
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to vaccines and immunoinformatics approaches